Cargando…
High rate of complete histopathological response in hepatocellular carcinoma patients after combined transarterial chemoembolization and stereotactic body radiation therapy
BACKGROUND: Liver transplantation (LT) presents a curative treatment option in patients with early stage hepatocellular carcinoma (HCC) who are not eligible for resection or ablation therapy. Due to a risk of up 30% for waitlist drop-out upon tumor progression, bridging therapies are used to halt tu...
Autores principales: | , , , , , , , , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Baishideng Publishing Group Inc
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8240047/ https://www.ncbi.nlm.nih.gov/pubmed/34239274 http://dx.doi.org/10.3748/wjg.v27.i24.3630 |
_version_ | 1783715137418428416 |
---|---|
author | Bauer, Ulrike Gerum, Sabine Roeder, Falk Münch, Stefan Combs, Stephanie E Philipp, Alexander B De Toni, Enrico N Kirstein, Martha M Vogel, Arndt Mogler, Carolin Haller, Bernhard Neumann, Jens Braren, Rickmer F Makowski, Marcus R Paprottka, Philipp Guba, Markus Geisler, Fabian Schmid, Roland M Umgelter, Andreas Ehmer, Ursula |
author_facet | Bauer, Ulrike Gerum, Sabine Roeder, Falk Münch, Stefan Combs, Stephanie E Philipp, Alexander B De Toni, Enrico N Kirstein, Martha M Vogel, Arndt Mogler, Carolin Haller, Bernhard Neumann, Jens Braren, Rickmer F Makowski, Marcus R Paprottka, Philipp Guba, Markus Geisler, Fabian Schmid, Roland M Umgelter, Andreas Ehmer, Ursula |
author_sort | Bauer, Ulrike |
collection | PubMed |
description | BACKGROUND: Liver transplantation (LT) presents a curative treatment option in patients with early stage hepatocellular carcinoma (HCC) who are not eligible for resection or ablation therapy. Due to a risk of up 30% for waitlist drop-out upon tumor progression, bridging therapies are used to halt tumor growth. Transarterial chemoembolization (TACE) and less commonly stereotactic body radiation therapy (SBRT) or a combination of TACE and SBRT, are used as bridging therapies in LT. However, it remains unclear if one of those treatment options is superior. The analysis of explant livers after transplantation provides the unique opportunity to investigate treatment response by histopathology. AIM: To analyze histopathological response to a combination of TACE and SBRT in HCC in comparison to TACE or SBRT alone. METHODS: In this multicenter retrospective study, 27 patients who received liver transplantation for HCC were analyzed. Patients received either TACE or SBRT alone, or a combination of TACE and SBRT as bridging therapy to liver transplantation. Liver explants of all patients who received at least one TACE and/or SBRT were analyzed for the presence of residual vital tumor tissue by histopathology to assess differences in treatment response to bridging therapies. Statistical analysis was performed using Fisher-Freeman-Halton exact test, Kruskal-Wallis and Mann-Whitney-U tests. RESULTS: Fourteen patients received TACE only, four patients SBRT only, and nine patients a combination therapy of TACE and SBRT. There were no significant differences between groups regarding age, sex, etiology of underlying liver disease or number and size of tumor lesions. Strikingly, analysis of liver explants revealed that almost all patients in the TACE and SBRT combination group (8/9, 89%) showed no residual vital tumor tissue by histopathology, whereas TACE or SBRT alone resulted in significantly lower rates of complete histopathological response (0/14, 0% and 1/4, 25%, respectively, P value < 0.001). CONCLUSION: Our data suggests that a combination of TACE and SBRT increases the rate of complete histopathological response compared to TACE or SBRT alone in bridging to liver transplantation. |
format | Online Article Text |
id | pubmed-8240047 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | Baishideng Publishing Group Inc |
record_format | MEDLINE/PubMed |
spelling | pubmed-82400472021-07-07 High rate of complete histopathological response in hepatocellular carcinoma patients after combined transarterial chemoembolization and stereotactic body radiation therapy Bauer, Ulrike Gerum, Sabine Roeder, Falk Münch, Stefan Combs, Stephanie E Philipp, Alexander B De Toni, Enrico N Kirstein, Martha M Vogel, Arndt Mogler, Carolin Haller, Bernhard Neumann, Jens Braren, Rickmer F Makowski, Marcus R Paprottka, Philipp Guba, Markus Geisler, Fabian Schmid, Roland M Umgelter, Andreas Ehmer, Ursula World J Gastroenterol Retrospective Study BACKGROUND: Liver transplantation (LT) presents a curative treatment option in patients with early stage hepatocellular carcinoma (HCC) who are not eligible for resection or ablation therapy. Due to a risk of up 30% for waitlist drop-out upon tumor progression, bridging therapies are used to halt tumor growth. Transarterial chemoembolization (TACE) and less commonly stereotactic body radiation therapy (SBRT) or a combination of TACE and SBRT, are used as bridging therapies in LT. However, it remains unclear if one of those treatment options is superior. The analysis of explant livers after transplantation provides the unique opportunity to investigate treatment response by histopathology. AIM: To analyze histopathological response to a combination of TACE and SBRT in HCC in comparison to TACE or SBRT alone. METHODS: In this multicenter retrospective study, 27 patients who received liver transplantation for HCC were analyzed. Patients received either TACE or SBRT alone, or a combination of TACE and SBRT as bridging therapy to liver transplantation. Liver explants of all patients who received at least one TACE and/or SBRT were analyzed for the presence of residual vital tumor tissue by histopathology to assess differences in treatment response to bridging therapies. Statistical analysis was performed using Fisher-Freeman-Halton exact test, Kruskal-Wallis and Mann-Whitney-U tests. RESULTS: Fourteen patients received TACE only, four patients SBRT only, and nine patients a combination therapy of TACE and SBRT. There were no significant differences between groups regarding age, sex, etiology of underlying liver disease or number and size of tumor lesions. Strikingly, analysis of liver explants revealed that almost all patients in the TACE and SBRT combination group (8/9, 89%) showed no residual vital tumor tissue by histopathology, whereas TACE or SBRT alone resulted in significantly lower rates of complete histopathological response (0/14, 0% and 1/4, 25%, respectively, P value < 0.001). CONCLUSION: Our data suggests that a combination of TACE and SBRT increases the rate of complete histopathological response compared to TACE or SBRT alone in bridging to liver transplantation. Baishideng Publishing Group Inc 2021-06-28 2021-06-28 /pmc/articles/PMC8240047/ /pubmed/34239274 http://dx.doi.org/10.3748/wjg.v27.i24.3630 Text en ©The Author(s) 2020. Published by Baishideng Publishing Group Inc. All rights reserved. https://creativecommons.org/licenses/by-nc/4.0/This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. |
spellingShingle | Retrospective Study Bauer, Ulrike Gerum, Sabine Roeder, Falk Münch, Stefan Combs, Stephanie E Philipp, Alexander B De Toni, Enrico N Kirstein, Martha M Vogel, Arndt Mogler, Carolin Haller, Bernhard Neumann, Jens Braren, Rickmer F Makowski, Marcus R Paprottka, Philipp Guba, Markus Geisler, Fabian Schmid, Roland M Umgelter, Andreas Ehmer, Ursula High rate of complete histopathological response in hepatocellular carcinoma patients after combined transarterial chemoembolization and stereotactic body radiation therapy |
title | High rate of complete histopathological response in hepatocellular carcinoma patients after combined transarterial chemoembolization and stereotactic body radiation therapy |
title_full | High rate of complete histopathological response in hepatocellular carcinoma patients after combined transarterial chemoembolization and stereotactic body radiation therapy |
title_fullStr | High rate of complete histopathological response in hepatocellular carcinoma patients after combined transarterial chemoembolization and stereotactic body radiation therapy |
title_full_unstemmed | High rate of complete histopathological response in hepatocellular carcinoma patients after combined transarterial chemoembolization and stereotactic body radiation therapy |
title_short | High rate of complete histopathological response in hepatocellular carcinoma patients after combined transarterial chemoembolization and stereotactic body radiation therapy |
title_sort | high rate of complete histopathological response in hepatocellular carcinoma patients after combined transarterial chemoembolization and stereotactic body radiation therapy |
topic | Retrospective Study |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8240047/ https://www.ncbi.nlm.nih.gov/pubmed/34239274 http://dx.doi.org/10.3748/wjg.v27.i24.3630 |
work_keys_str_mv | AT bauerulrike highrateofcompletehistopathologicalresponseinhepatocellularcarcinomapatientsaftercombinedtransarterialchemoembolizationandstereotacticbodyradiationtherapy AT gerumsabine highrateofcompletehistopathologicalresponseinhepatocellularcarcinomapatientsaftercombinedtransarterialchemoembolizationandstereotacticbodyradiationtherapy AT roederfalk highrateofcompletehistopathologicalresponseinhepatocellularcarcinomapatientsaftercombinedtransarterialchemoembolizationandstereotacticbodyradiationtherapy AT munchstefan highrateofcompletehistopathologicalresponseinhepatocellularcarcinomapatientsaftercombinedtransarterialchemoembolizationandstereotacticbodyradiationtherapy AT combsstephaniee highrateofcompletehistopathologicalresponseinhepatocellularcarcinomapatientsaftercombinedtransarterialchemoembolizationandstereotacticbodyradiationtherapy AT philippalexanderb highrateofcompletehistopathologicalresponseinhepatocellularcarcinomapatientsaftercombinedtransarterialchemoembolizationandstereotacticbodyradiationtherapy AT detonienricon highrateofcompletehistopathologicalresponseinhepatocellularcarcinomapatientsaftercombinedtransarterialchemoembolizationandstereotacticbodyradiationtherapy AT kirsteinmartham highrateofcompletehistopathologicalresponseinhepatocellularcarcinomapatientsaftercombinedtransarterialchemoembolizationandstereotacticbodyradiationtherapy AT vogelarndt highrateofcompletehistopathologicalresponseinhepatocellularcarcinomapatientsaftercombinedtransarterialchemoembolizationandstereotacticbodyradiationtherapy AT moglercarolin highrateofcompletehistopathologicalresponseinhepatocellularcarcinomapatientsaftercombinedtransarterialchemoembolizationandstereotacticbodyradiationtherapy AT hallerbernhard highrateofcompletehistopathologicalresponseinhepatocellularcarcinomapatientsaftercombinedtransarterialchemoembolizationandstereotacticbodyradiationtherapy AT neumannjens highrateofcompletehistopathologicalresponseinhepatocellularcarcinomapatientsaftercombinedtransarterialchemoembolizationandstereotacticbodyradiationtherapy AT brarenrickmerf highrateofcompletehistopathologicalresponseinhepatocellularcarcinomapatientsaftercombinedtransarterialchemoembolizationandstereotacticbodyradiationtherapy AT makowskimarcusr highrateofcompletehistopathologicalresponseinhepatocellularcarcinomapatientsaftercombinedtransarterialchemoembolizationandstereotacticbodyradiationtherapy AT paprottkaphilipp highrateofcompletehistopathologicalresponseinhepatocellularcarcinomapatientsaftercombinedtransarterialchemoembolizationandstereotacticbodyradiationtherapy AT gubamarkus highrateofcompletehistopathologicalresponseinhepatocellularcarcinomapatientsaftercombinedtransarterialchemoembolizationandstereotacticbodyradiationtherapy AT geislerfabian highrateofcompletehistopathologicalresponseinhepatocellularcarcinomapatientsaftercombinedtransarterialchemoembolizationandstereotacticbodyradiationtherapy AT schmidrolandm highrateofcompletehistopathologicalresponseinhepatocellularcarcinomapatientsaftercombinedtransarterialchemoembolizationandstereotacticbodyradiationtherapy AT umgelterandreas highrateofcompletehistopathologicalresponseinhepatocellularcarcinomapatientsaftercombinedtransarterialchemoembolizationandstereotacticbodyradiationtherapy AT ehmerursula highrateofcompletehistopathologicalresponseinhepatocellularcarcinomapatientsaftercombinedtransarterialchemoembolizationandstereotacticbodyradiationtherapy |